Arena has raised $200 million in a Series B funding round at a $2.88 billion post-money valuation. The round closed on 22 September 2026, bringing the AI evaluation startup's total funding to approximately $450 million. The company launched its Alignment Index on 8 October 2026, a benchmark measuring AI agent safety across three metrics: unauthorised action, false attribution, and deceptive completion. The index draws from over 90,000 agent sessions spanning 27 models. Arena's commercial AI Evaluations product reached an estimated annualised run-rate of $100 million by June 2026, up from $30 million in January. The company charges on a consumption basis rather than fixed subscriptions. Investors include Andreessen Horowitz, Felicis, UC Investments, Kleiner Perkins, and Lightspeed. Arena began as an open-source project at UC Berkeley in April 2023 before incorporating in April 2025.

NewLimit, a South San Francisco biotech co-founded by CEO Jacob Kimmel, Coinbase's Brian Armstrong and investor Blake Byers, has raised $682 million to develop anti-aging drugs based on epigenetic reprogramming. The company has been named an Endpoints 11 2026 winner. Backers include Kleiner Perkins, Founders Fund, Dimension Capital, Eli Lilly Ventures and Thrive Capital. The funding is unusually large for a private firm working on aging biology, a field that has yet to produce an approved drug. NewLimit's approach involves partially resetting gene regulation patterns in cells to restore youthful function without triggering cancer risk. The company must eventually select a specific disease indication for clinical trials, as no regulatory pathway currently treats aging itself. The capital provides runway to develop candidates before committing to human studies.